Home
About Us
>At a Glance
>Global Recognition
>History and Milestones
>Management Team
>Brochure
Therapeutic Focus
>Oncology
>Autoimmune Diseases
Products
>Pipeline Overview
>HMPL-004
>HMPL-011
>HMPL-012
>HMPL-013
>HMPL-813
Research & Development
>Drug Discovery Research
>Drug Development
>Facility and Capacity
Collaborations
>Overview
>Existing Partnerships
Principles
>CEO Statement
>Mission and Values
Media
>Key Facts
>Press Releases
>Featured Articles
Careers
Contacts
About Us
Hutchison MediPharma is an internationally focused biotechnology company focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases.
Product Pipeline
Hutchison MediPharma has a pipeline of clinical phase therapeutics for cancer and autoimmune diseases.
Latest News
11/05/2009
Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved, Proceeding with Development and Partnership Plans
10/30/2009
Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Autoimmune Diseases
Recent Awards
